rs138421850

Variant summary

Our verdict is Benign. The variant received -20 ACMG points: 0P and 20B. BP4_StrongBP6_Very_StrongBS1BS2

The NM_020822.3(KCNT1):​c.3388G>A​(p.Ala1130Thr) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0123 in 1,576,966 control chromosomes in the GnomAD database, including 159 homozygotes. In-silico tool predicts a benign outcome for this variant. 14/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Likely benign (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. A1130V) has been classified as Likely benign.

Frequency

Genomes: 𝑓 0.0098 ( 15 hom., cov: 33)
Exomes 𝑓: 0.013 ( 144 hom. )

Consequence

KCNT1
NM_020822.3 missense

Scores

2
16

Clinical Significance

Benign/Likely benign criteria provided, multiple submitters, no conflicts B:14

Conservation

PhyloP100: 1.13

Publications

10 publications found
Variant links:
Genes affected
KCNT1 (HGNC:18865): (potassium sodium-activated channel subfamily T member 1) Potassium channels represent the most complex class of voltage-gated ion channels from both functional and structural standpoints. Their diverse functions include regulating neurotransmitter release, heart rate, insulin secretion, neuronal excitability, epithelial electrolyte transport, smooth muscle contraction, and cell volume. This gene encodes a sodium-activated potassium channel subunit which is thought to function in ion conductance and developmental signaling pathways. Mutations in this gene cause the early-onset epileptic disorders, malignant migrating partial seizures of infancy and autosomal dominant nocturnal frontal lobe epilepsy. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Dec 2012]
KCNT1 Gene-Disease associations (from GenCC):
  • childhood-onset epilepsy syndrome
    Inheritance: AD Classification: DEFINITIVE Submitted by: ClinGen
  • developmental and epileptic encephalopathy, 14
    Inheritance: AD Classification: DEFINITIVE, STRONG, MODERATE Submitted by: Labcorp Genetics (formerly Invitae), Ambry Genetics, G2P
  • malignant migrating partial seizures of infancy
    Inheritance: AD Classification: DEFINITIVE, SUPPORTIVE Submitted by: G2P, Orphanet
  • autosomal dominant nocturnal frontal lobe epilepsy 5
    Inheritance: AD Classification: STRONG, MODERATE Submitted by: Ambry Genetics, Labcorp Genetics (formerly Invitae)
  • autosomal dominant nocturnal frontal lobe epilepsy
    Inheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -20 ACMG points.

BP4
Computational evidence support a benign effect (MetaRNN=0.004505396).
BP6
Variant 9-135786407-G-A is Benign according to our data. Variant chr9-135786407-G-A is described in ClinVar as Benign/Likely_benign. ClinVar VariationId is 129364.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
BS1
Variant frequency is greater than expected in population amr. GnomAd4 allele frequency = 0.00978 (1489/152318) while in subpopulation AMR AF = 0.0142 (217/15312). AF 95% confidence interval is 0.0126. There are 15 homozygotes in GnomAd4. There are 747 alleles in the male GnomAd4 subpopulation. Median coverage is 33. This position passed quality control check.
BS2
High AC in GnomAd4 at 1489 AD gene.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
KCNT1NM_020822.3 linkc.3388G>A p.Ala1130Thr missense_variant Exon 29 of 31 ENST00000371757.7 NP_065873.2 Q5JUK3-3

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
KCNT1ENST00000371757.7 linkc.3388G>A p.Ala1130Thr missense_variant Exon 29 of 31 1 NM_020822.3 ENSP00000360822.2 Q5JUK3-3

Frequencies

GnomAD3 genomes
AF:
0.00980
AC:
1491
AN:
152202
Hom.:
15
Cov.:
33
show subpopulations
Gnomad AFR
AF:
0.00285
Gnomad AMI
AF:
0.0132
Gnomad AMR
AF:
0.0142
Gnomad ASJ
AF:
0.00662
Gnomad EAS
AF:
0.000193
Gnomad SAS
AF:
0.00911
Gnomad FIN
AF:
0.0121
Gnomad MID
AF:
0.0159
Gnomad NFE
AF:
0.0133
Gnomad OTH
AF:
0.0191
GnomAD2 exomes
AF:
0.0104
AC:
1844
AN:
176890
AF XY:
0.0106
show subpopulations
Gnomad AFR exome
AF:
0.00315
Gnomad AMR exome
AF:
0.00814
Gnomad ASJ exome
AF:
0.00845
Gnomad EAS exome
AF:
0.0000745
Gnomad FIN exome
AF:
0.0148
Gnomad NFE exome
AF:
0.0140
Gnomad OTH exome
AF:
0.0115
GnomAD4 exome
AF:
0.0126
AC:
17924
AN:
1424648
Hom.:
144
Cov.:
36
AF XY:
0.0125
AC XY:
8818
AN XY:
705736
show subpopulations
African (AFR)
AF:
0.00199
AC:
65
AN:
32602
American (AMR)
AF:
0.00988
AC:
393
AN:
39766
Ashkenazi Jewish (ASJ)
AF:
0.00772
AC:
197
AN:
25512
East Asian (EAS)
AF:
0.00
AC:
0
AN:
37690
South Asian (SAS)
AF:
0.00887
AC:
732
AN:
82522
European-Finnish (FIN)
AF:
0.0136
AC:
665
AN:
48808
Middle Eastern (MID)
AF:
0.0163
AC:
78
AN:
4780
European-Non Finnish (NFE)
AF:
0.0137
AC:
15023
AN:
1094112
Other (OTH)
AF:
0.0131
AC:
771
AN:
58856
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.489
Heterozygous variant carriers
0
1103
2205
3308
4410
5513
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Exome Hom
Variant carriers
0
568
1136
1704
2272
2840
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.00978
AC:
1489
AN:
152318
Hom.:
15
Cov.:
33
AF XY:
0.0100
AC XY:
747
AN XY:
74482
show subpopulations
African (AFR)
AF:
0.00284
AC:
118
AN:
41588
American (AMR)
AF:
0.0142
AC:
217
AN:
15312
Ashkenazi Jewish (ASJ)
AF:
0.00662
AC:
23
AN:
3472
East Asian (EAS)
AF:
0.000193
AC:
1
AN:
5170
South Asian (SAS)
AF:
0.00911
AC:
44
AN:
4828
European-Finnish (FIN)
AF:
0.0121
AC:
128
AN:
10622
Middle Eastern (MID)
AF:
0.0171
AC:
5
AN:
292
European-Non Finnish (NFE)
AF:
0.0133
AC:
902
AN:
68006
Other (OTH)
AF:
0.0184
AC:
39
AN:
2116
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.504
Heterozygous variant carriers
0
79
158
236
315
394
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Genome Hom
Variant carriers
0
20
40
60
80
100
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.00751
Hom.:
8
Bravo
AF:
0.00951
TwinsUK
AF:
0.0108
AC:
40
ALSPAC
AF:
0.0145
AC:
56
ESP6500AA
AF:
0.00246
AC:
10
ESP6500EA
AF:
0.0106
AC:
85
ExAC
AF:
0.00790
AC:
909
Asia WGS
AF:
0.00491
AC:
17
AN:
3476

ClinVar

Significance: Benign/Likely benign
Submissions summary: Benign:14
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

not specified Benign:5
Jul 17, 2014
Eurofins Ntd Llc (ga)
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

-
Genetic Services Laboratory, University of Chicago
Significance:Likely benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

Likely benign based on allele frequency in 1000 Genomes Project or ESP global frequency and its presence in a patient with a rare or unrelated disease phenotype. NOT Sanger confirmed. -

Jan 14, 2016
GeneDx
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. -

-
Genome Diagnostics Laboratory, University Medical Center Utrecht
Significance:Benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

- -

-
PreventionGenetics, part of Exact Sciences
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

not provided Benign:4
Jun 01, 2025
CeGaT Center for Human Genetics Tuebingen
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

KCNT1: BP4, BS1, BS2 -

-
Breakthrough Genomics, Breakthrough Genomics
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:not provided

- -

Dec 15, 2016
Center for Pediatric Genomic Medicine, Children's Mercy Hospital and Clinics
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

-
Laboratory of Diagnostic Genome Analysis, Leiden University Medical Center (LUMC)
Significance:Likely benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

- -

Autosomal dominant nocturnal frontal lobe epilepsy 5 Benign:2
Mar 15, 2022
Genome-Nilou Lab
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Jul 05, 2019
Centre for Mendelian Genomics, University Medical Centre Ljubljana
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This variant was classified as: Benign. The following ACMG criteria were applied in classifying this variant: BS1,BS2. -

Developmental and epileptic encephalopathy, 14;C3554306:Autosomal dominant nocturnal frontal lobe epilepsy 5 Benign:1
Feb 04, 2025
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Inborn genetic diseases Benign:1
Apr 15, 2016
Ambry Genetics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This alteration is classified as benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. -

Developmental and epileptic encephalopathy, 14 Benign:1
Mar 15, 2022
Genome-Nilou Lab
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
0.073
BayesDel_addAF
Benign
-0.62
T
BayesDel_noAF
Benign
-0.65
CADD
Benign
5.0
DANN
Benign
0.90
DEOGEN2
Benign
0.030
.;.;.;.;.;.;.;.;T;.
Eigen
Benign
-1.6
Eigen_PC
Benign
-1.7
FATHMM_MKL
Benign
0.13
N
LIST_S2
Benign
0.74
T;T;T;T;T;T;T;T;T;T
MetaRNN
Benign
0.0045
T;T;T;T;T;T;T;T;T;T
MetaSVM
Benign
-1.0
T
MutationAssessor
Uncertain
2.2
.;.;.;.;.;.;.;.;M;.
PhyloP100
1.1
PrimateAI
Benign
0.36
T
PROVEAN
Benign
-0.67
N;.;N;.;.;.;.;.;.;N
REVEL
Benign
0.028
Sift
Uncertain
0.012
D;.;T;.;.;.;.;.;.;T
Sift4G
Benign
0.45
T;T;T;T;T;T;T;T;T;T
Vest4
0.25
MPC
0.092
ClinPred
0.0033
T
GERP RS
-1.1
Varity_R
0.028
gMVP
0.37
Mutation Taster
=100/0
polymorphism

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs138421850; hg19: chr9-138678253; COSMIC: COSV53712185; COSMIC: COSV53712185; API